ViRexx Medical Corp.
TSX : VIR

ViRexx Medical Corp.

November 15, 2005 11:29 ET

ViRexx to Present at Technology Finance 2005

EDMONTON, ALBERTA--(CCNMatthews - Nov. 15, 2005) - ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that Marc Canton, President and Chief Operating Officer of ViRexx, is scheduled to present at the upcoming Technology Finance Conference 2005 in Milan, Italy. The presentation is scheduled for 11:20 a.m. (local time) on Thursday, November 17, 2005. The Technology Finance Conference will be held from November 17-18, 2005 at the Jolly Hotel President in Milan.

The Technology Finance Conference is focused on emerging growth nanotech, high tech, biotech, medical and biometric companies from cutting edge backgrounds, including innovative research vehicles and life enhancing pipelines. The event brings together companies and institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B & C and solid tumors.

ViRexx's lead product, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX has not approved or disapproved of the information contained herein.

Contact Information

  • ViRexx Medical Corp.
    Marc Canton
    Chief Operating Officer
    (780) 989-6717
    (780) 436-0068 (FAX)
    Email: mcanton@virexx.com
    Website: www.virexx.com
    or
    The Equicom Group Inc.
    Ross Marshall
    Investor Relations
    (800) 385 5451 ext. 238
    (416) 815-0080 (FAX)
    Email: rmarshall@equicomgroup.com
    or
    Lippert/Heilshorn & Associates Inc.
    Kim Golodetz
    Investor Relations
    (212) 838 -3777
    (212) 838 -4568 (FAX)
    Email: kgolodetz@lhai.com